Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer

According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among … Read More

Cleveland Clinic Researchers Validate Link Between Genetic Variant and Poor Outcomes in Men with Advanced Prostate Cancer

In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that … Read More

Cleveland Clinic Study Identifies Genetic Anomaly Associated with Poor Response to Common Asthma Treatment

A new Cleveland Clinic study has uncovered a genetic anomaly associated with poor response to a common asthma treatment. The findings, published in Proceedings of the National Academy of Sciences, showed that asthmatic patients with the gene variant are less likely to respond to glucocorticoids and often develop severe asthma. The research team, led by … Read More

Jack, Joseph and Morton Mandel Foundation Gives $1 Million to Endowed Chair in Urologic Cancer Research at Cleveland Clinic

The Jack, Joseph and Morton Mandel Foundation has donated $1 million to establish the Morton L. Mandel Chair for Urologic Cancer Research at Cleveland Clinic. The gift was matched directly by Cleveland Clinic to endow a chair that will support innovative work in the newly formed Cleveland Clinic Center for Genitourinary (GU) Malignancies Research, a … Read More

Cleveland Clinic Researchers Find New Gene Variant Linked to Deadly Prostate Cancer

Cleveland Clinic researchers have confirmed for the first time a mechanistic link between the gene HSD17B4 and deadly, treatment-resistant prostate cancer. The research, led by Nima Sharifi, M.D., Cleveland Clinic Lerner Research Institute, Department of Cancer Biology, shows that men who lack a certain subtype of the gene may be more susceptible to aggressive prostate … Read More

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment

Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized treatment plan that targets specific hormonal … Read More

Cleveland Clinic Researchers Discover Similarities Between Next-Generation Prostate Cancer Drugs

  Cleveland Clinic researchers have shown for the first time how a class of advanced prostate cancer drugs are processed in the body and how their anti-tumor activity might change depending on how they are metabolized. Their pre-clinical findings, just published in Cell Chemical Biology, may lay the foundation for improving therapies for treatment-resistant, aggressive … Read More

Cleveland Clinic Researcher Receives Top Ten Clinical Research Achievement Award

Cleveland Clinic physician-researcher Nima Sharifi, M.D. was recognized as a Top Ten Clinical Research Achievement awardee by the Clinical Research (CR) Forum, a national organization of senior researchers and thought leaders from the nation’s leading academic health centers. Dr. Sharifi was selected for his research published in the October 2016 edition of The Lancet Oncology, … Read More

Cleveland Clinic Researchers Reverse Prostate Cancer Drug Resistance

A Cleveland Clinic research team has uncovered a biological pathway that renders a common prostate cancer drug useless and, for the first time, restored the drug’s cancer-killing power in human prostate cancer tumor cells grown in mice. Results from the study were published online today in the medical journal, eLife. Resistance to prostate cancer drugs … Read More